New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:44 EDTMGNXMacroGenics reports milestone in DART program triggers $20M in payments
MacroGenics announced that Servier, France's largest privately-held pharmaceutical company, has exercised its exclusive option to develop and commercialize MGD006, a DART-based product candidate developed by MacroGenics. Servier will gain exclusive development and commercial rights in all countries outside of the U.S., Canada, Mexico, Japan, South Korea and India. In those countries, MacroGenics will retain development and commercialization rights. As a result of the exercise, MacroGenics will receive a $15M payment from Servier. In addition, the Investigational New Drug application for MGD006 has cleared the 30 day review period by the U.S. Food and Drug Administration, triggering an additional $5M payment to MacroGenics by Servier.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:47 EDTMGNXMacroGenics has compelling pipeline opportunities, says Roth Capital
Subscribe for More Information
November 18, 2014
07:20 EDTMGNXEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 12, 2014
11:17 EDTMGNXLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:21 EDTMGNXMacroGenics strategic change positive, says Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use